CLASS II ONGOING Drug recall · Reported 10 Jun 2026 · FDA Enforcement Report

Duloxetine DR Capsules, 30 mg, Rx, Relabeled recalled by Asclemed USA

Asclemed USA is recalling Duloxetine DR Capsules, 30 mg, Rx, Relabeled by: Enovachem Pharmaceuticals, Torrance, CA, distributed nationwide in the US. The recall was initiated on 14 May 2026 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot # 050725G-30 & 050725F-30, Exp Date: 06/30/2026
NDC76420-623, 76420-633, 76420-634, 76420-636
Quantity recalled50 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0555-2026
FDA event ID
99019
Recalling firm
Asclemed USA, Torrance, CA
Manufacturer
Asclemed USA, Inc.
Classification
Class II
Status
Ongoing
Recall initiated
14 May 2026
FDA classified
2 Jun 2026
Reported
10 Jun 2026
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity
Drug class
Antidepressants

Timeline

14 May 2026Recall initiated by company
2 Jun 2026Classified by FDA+19 days
10 Jun 2026Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit.

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Duloxetine DR Capsules, 30 mg, 30 count bottles, Rx, Relabeled by: Enovachem Pharmaceuticals, Torrance, CA 90501, NDC 76420-634-30, Marketed by: Ajanta Pharma USA Inc.

Where it was distributed

US Nationwide.

Nationwide

Questions about this recall

Why was it recalled?

CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit.

Which lots are affected?

Lot # 050725G-30 & 050725F-30, Exp Date: 06/30/2026

Where was it sold?

US Nationwide.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Asclemed USA

All 10

Other Duloxetine recalls

All 57